|
[1] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology,2016,64(1):73-84.
|
|
[2] CHALASANI N,YOUNOSSI Z,LAVINE JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357.
|
|
[3] CALZADILLA BERTOT L,ADAMS LA. The natural course of non-alcoholic fatty liver disease[J]. Int J Mol Sci,2016,17(5):774-786.
|
|
[4] WANG ZT,HU RH,XIONG Y. Progress of treatment on nonalcoholic fatty liver disease[J/CD]. Chin J Liver Dis(Electronic Edition),2018,10(4):48-53.(in Chinese)王中涛，胡荣华，熊勇．非酒精性脂肪性肝病治疗进展[J/CD]．中国肝脏病杂志(电子版)，2018,10(4):48-53.
|
|
[5] LIANG Y,LIN C,ZHANG Y,et al. Probiotic mixture of Lactobacillus and Bifidobacterium alleviates systemic adiposity and inflammation in non-alcoholic fatty liver disease rats through Gpr109a and the commensal metabolite butyrate[J]. Inflammopharmacology,2018,26(4):1051-1055.
|
|
[6] ENDO H,NIIOKA M,KOBAYASHI N,et al. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats:New insight into the probiotics for the gut-liver axis[J]. PLo S One,2013,8(5):e63388.
|
|
[7] FAITH JJ,GURUGE JL,CHARBONNEAU M,et al. The long-term stability of the human gut microbiota[J]. Science,2013,341(6141):1237439.
|
|
[8] SALTZMAN ET,PALACIOS T,THOMSEN M,et al. Intestinal microbiome shifts,dysbiosis,inflammation,and non-alcoholic fatty liver disease[J]. Front Microbiol,2018,9:61.
|
|
[9] KOLODZIEJCZYK AA,ZHENG D,SHIBOLET O,et al. The role of the microbiome in NAFLD and NASH[J]. EMBO Mol Med,2019,11(2):e9302.
|
|
[10] KAU AL,AHERN PP,GRIFFIN NW,et al. Human nutrition,the gut microbiome and the immune system[J]. Nature,2011,474(7351):327-336.
|
|
[11] CHEN Y,CAO YS,LIU XH. Short chain fatty acids and intestinal microflora[J]. Jiangxi Sci,2006,24(1):38-40,69.(in Chinese)陈燕，曹郁生，刘晓华．短链脂肪酸与肠道菌群[J]．江西科学，2006,24(1):38-40,69.
|
|
[12] WIEST R,ALBILLOS A,TRAUNER M,et al. Targeting the gutliver axis in liver disease[J]. J Hepatol,2017,67(5):1084-1103.
|
|
[13] FUKUDA S,TOH H,HASE K,et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate[J]. Nature,2011,469(7331):543-547.
|
|
[14] SAFARI Z,GRARD P. The links between the gut microbiome and non-alcoholic fatty liver disease(NAFLD)[J]. Cell Mol Life Sci,2019,76(8):1541-1558.
|
|
[15] ZHANG WH,JIANG Y,ZHU QF,et al. Sodium butyrate maintains growth performance by regulating the immune response in broiler chickens[J]. Br Poult Sci,2011,52(3):292-301.
|
|
[16] PLGER S,STUMPFF F,PENNER GB,et al. Microbial butyrate and its role for barrier function in the gastrointestinal tract[J]. Ann N Y Acad Sci,2012,1258:52-59.
|
|
[17] ZHOU D,PAN Q,XIN FZ,et al. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier[J]. World J Gastroenterol,2017,23(1):60-75.
|
|
[18] ZENG X,YANG J,HU O,et al. Dihydromyricetin ameliorates nonalcoholic fatty liver disease by improving mitochondrial respiratory capacity and redox homeostasis through modulation of SIRT3 signaling[J]. Antioxid Redox Signal,2019,30(2):163-183.
|
|
[19] CHEN M,HUI S,LANG H,et al. SIRT3 deficiency promotes high-fat diet-induced nonalcoholic fatty liver disease in correlation with impaired intestinal permeability through gut microbial dysbiosis[J]. Mol Nutr Food Res, 2019, 63(4):e1800612.
|
|
[20] FEINGOLD KR,MOSER A,SHIGENAGA JK,et al. Inflammation stimulates niacin receptor(GPR109A/HCA2)expression in adipose tissue and macrophages[J]. J Lipid Res,2014,55(12):2501-2508.
|
|
[21] KOH A,de VADDER F,KOVATCHEVA-DATCHARY P,et al.From dietary fiber to host physiology:Short-chain fatty acids as key bacterial metabolites[J]. Cell,2016,165(6):1332-1345.
|
|
[22] AGRAWAL S,DUSEJA AK. Non-alcoholic fatty liver disease:East versus west[J]. J Clin Exp Hepatol,2012,2(2):122-134.
|
|
[23] ROTTER V,NAGAEV I,SMITH U. Interleukin-6(IL-6)induces insulin resistance in 3T3-L1 adipocytes and is,like IL-8 and tumor necrosis factor-alpha,overexpressed in human fat cells from insulin-resistant subjects[J]. J Biol Chem,2003,278(46):45777-45784.
|
|
[24] BHAKTA HK,PAUDEL P,FUJII H,et al. Oligonol promotes glucose uptake by modulating the insulin signaling pathway in insulin-resistant HepG2 cells via inhibiting protein tyrosine phosphatase 1B[J]. Arch Pharm Res,2017,40(11):1314-1327.
|
|
[25] LU V,BOGDANOVIC E,YU Z,et al. Combined Hyperglycemia-and hyperinsulinemia-induced insulin resistance in adipocytes is associated with dual signaling defects mediated by PKC-ζ[J]. Endocrinology,2018,159(4):1658-1677.
|
|
[26] ZHANG QN,XIAO Y,MIAO RX,et al. Changes in intestinal flora in nonalcoholic fatty liver disease:Their correlation with insulin resistance index,tumor necrosis factor-α，and interleukin-6[J]. J Clin Hepatol,2015,31(7):1078-1081.(in Chinese)张秋楠，肖英，苗瑞新，等．非酒精性脂肪性肝病患者肠道菌群变化与胰岛素抵抗指数、肿瘤坏死因子α和白细胞介素6的相关性分析[J]．临床肝胆病杂志，2015,31(7):1078-1081.
|
|
[27] RABOT S,MEMBREZ M,BRUNEAU A,et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism[J].FASEB J,2010,24(12):4948-4959.
|
|
[28] MATTACE RASO G,SIMEOLI R,RUSSO R,et al. Effects of sodium butyrate and its synthetic amide derivative on liver inflammation and glucose tolerance in an animal model of steatosis induced by high fat diet[J]. PLo S One,2013,8(7):e68626.
|
|
[29] HENAGAN TM,STEFANSKA B,FANG Z,et al. Sodium butyrate epigenetically modulates high-fat diet-induced skeletal muscle mitochondrial adaptation,obesity and insulin resistance through nucleosome positioning[J]. Br J Pharmacol,2015,172(11):2782-2798.
|
|
[30] CHRIETT S,ZERZAIHI O,VIDAL H,et al. The histone deacetylase inhibitor sodium butyrate improves insulin signalling in palmitate-induced insulin resistance in L6 rat muscle cells through epigenetically-mediated up-regulation of Irs1[J]. Mol Cel Endocrinol,2017,439:224-232.
|
|
[31] MOLLICA MP,MATTACE RASO G,CAVALIERE G,et al. Butyrate regulates liver mitochondrial function,efficiency,and dynamics in insulin-resistant obese mice[J]. Diabetes,2017,66(5):1405-1418.
|
|
[32] NAKAMURA S,TAKAMURA T,MATSUZAWA-NAGATA N,et al. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria[J]. J Biol Chem,2009,284(22):14809-14818.
|
|
[33] CAVALIERE G,TRINCHESE G,BERGAMO P,et al. Polyunsaturated fatty acids attenuate diet induced obesity and insulin resistance,modulating mitochondrial respiratory uncoupling in rat skeletal muscle[J]. PLo S One,2016,11(2):e0149033.
|
|
[34] GARCIA-TREVIJANO ER,IRABURU MJ,FONTANA L,et al.Transforming growth factor beta1 induces the expression of alpha1(I)procollagen mRNA by a hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate cells[J].Hepatology,1999,29(3):960-970.
|
|
[35] ISHII T,ITOH K,TAKAHASHI S,et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages[J]. J Biol Chem,2000,275(21):16023-16029.
|
|
[36] ZHANG HM,ZHANG Y. Melatonin:A well-documented antioxidant with conditional pro-oxidant actions[J]. J Pineal Res,2014,57(2):131-146.
|
|
[37] HATZIS G,ZIAKAS P,KAVANTZAS N,et al. Melatonin attenuates high fat diet-induced fatty liver disease in rats[J].World J Hepatol,2013,5(4):160-169.
|
|
[38] JIN CJ,ENGSTLER AJ,SELLMANN C,et al. Sodium butyrate protects mice from the development of the early signs of nonalcoholic fatty liver disease:Role of melatonin and lipid peroxidation[J]. Br J Nutr,2016:1-12.
|
DownLoad: